Pulmonary Drug Delivery Systems Market - Forecasts From 2018 to 2023

November 2018 | 100 pages | ID: P35DB687466EN
Knowledge Sourcing Intelligence LLP

Abstracts

The Pulmonary Drug Delivery Systems market is projected to grow at a CAGR of 5.61% to reach US$51.538 billion by 2023, from US$37.145 billion in 2017. Increasing prevalence of chronic respiratory disease along with the rapid growing geriatric population is considered as the key driver for the growth of the pulmonary drug delivery systems market. According to World Health Organization nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle income countries. Moreover rising health awareness and increasing investment in healthcare and drug delivery industry by both public and private players is also expected to further fuel up the growth of the market.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Pulmonary Drug Delivery Systems value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the Pulmonary Drug Delivery Systems market.

Major industry players profiled as part of the report are Philips Respironics, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, 3M Healthcare and PARI GmbH among others.

Segmentation

The Pulmonary Drug Delivery Systems market has been analyzed through following segments:
By Product
Metered-dose inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Soft mist inhaler (SMI)
Nebulizers
By Distribution Channel
Offline
Online
By Geography
North America
USA
Canada
Mexico
Others
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
India
Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY PRODUCT

5.1. Metered-dose inhalers (MDIs)
5.2. Dry Powder Inhalers (DPIs)
5.3. Soft mist inhaler (SMI)
5.4. Nebulizers

6. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY DISTRIBUTION CHANNEL

6.1. Offline
6.2. Online

7. PULMONARY DRUG DELIVERY SYSTEMS MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. USA
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. United Kingdom
  7.3.4. Spain
  7.3.5. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. Israel
  7.4.3. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. Japan
  7.5.3. India
  7.5.4. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Philips Respironics
  9.1.1. Company Overview
  9.1.2. Financials
  9.1.3. Products and Services
  9.1.4. Recent Developments
9.2. GlaxoSmithKline plc
  9.2.1. Company Overview
  9.2.2. Financials
  9.2.3. Products and Services
  9.2.4. Recent Developments
9.3. Boehringer Ingelheim GmbH
  9.3.1. Company Overview
  9.3.2. Financials
  9.3.3. Products and Services
  9.3.4. Recent Developments
9.4. Teva Pharmaceutical Industries Ltd
  9.4.1. Company Overview
  9.4.2. Financials
  9.4.3. Products and Services
  9.4.4. Recent Developments
9.5. 3M Healthcare
  9.5.1. Company Overview
  9.5.2. Financials
  9.5.3. Products and Services
  9.5.4. Recent Developments
9.6. PARI GmbH
  9.6.1. Company Overview
  9.6.2. Financials
  9.6.3. Products and Services
  9.6.4. Recent Developments
9.7. F. Hoffmann-La Roche Ltd
  9.7.1. Company Overview
  9.7.2. Financials
  9.7.3. Products and Services
  9.7.4. Recent Developments
9.8. Gilbert Technologies
  9.8.1. Company Overview
  9.8.2. Financials
  9.8.3. Products and Services
  9.8.4. Recent Developments
9.9. AstraZeneca
  9.9.1. Company Overview
  9.9.2. Financials
  9.9.3. Products and Services
  9.9.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES
DISCLAIMER